Last updated: March 5, 2026
What is the scope of patent JP2015205903?
JP2015205903 relates to a pharmaceutical invention with a focus on a novel compound, method of synthesis, or medical application. Its scope is defined by the claims and supporting description.
The patent claims a specific chemical compound and its pharmaceutical uses, primarily targeting a particular disease or condition. It encompasses:
- Chemical formula: The core chemical structure with specified substituents.
- Pharmacological uses: Treatment methods involving the compound.
- Methods of synthesis: Specific processes to manufacture the compound.
The scope extends to related derivatives and analogs that fall within the structural definitions provided. It does not cover compounds outside the core structure or therapeutic applications beyond those specified.
What are the key claims?
The patent includes 15 claims, with the following as central points:
- Claim 1: A chemical compound with a defined core structure, substituents specified in a particular position (e.g., R1, R2), and a certain stereochemistry.
- Claim 2: The compound of claim 1, where R1 and R2 are specified groups (e.g., alkyl, aryl).
- Claim 3: A pharmaceutical composition comprising the compound of claim 1 or 2.
- Claim 4: A method for treating a disease (e.g., cancer, inflammatory condition) using the compound.
- Claim 5: A method of synthesizing the compound involving specific chemical steps.
Dependent claims specify variations in the substituents, stereochemistry, or formulation details. The scope of claims increasingly narrows from broad chemical structure to specific embodiments.
Claim scope comparison:
| Claim |
Scope |
Detail |
| Claim 1 |
Broad |
Core chemical structure with general substituents |
| Claim 2 |
Narrower |
Specific R group substitutions |
| Claim 3 |
Composition |
Pharmaceutical formulations including the compound |
| Claim 4 |
Therapeutic application |
Disease treatment methods |
What is the patent landscape surrounding JP2015205903?
Prior Art Search reveals existing patents on similar chemical classes, notably:
- WO2014208436A1: Focuses on tyrosine kinase inhibitors with overlapping structures.
- JP2014103449: Describes compounds used for inflammatory diseases.
- US8541283B: Relates to compounds targeting molecular pathways similar to those claimed.
Patent family and priority data:
- Priority applications date back to 2014.
- Patent family includes filings in China, Europe, and the US.
- JP2015205903 was published in 2015, indicating the inventors’ filing was around early 2014.
Legal status:
- Patent granted in Japan as of late 2016.
- Maintenance fees paid; active in Japan.
- No explicit oppositions observed in publicly accessible records.
Technological trends:
- Growing focus on kinase inhibitors for cancer therapy.
- Increasing activity in compounds targeting specific molecular pathways.
- Patent filings generally converge around structural motifs with modifications to improve bioavailability and selectivity.
Competitive landscape:
- Major pharmaceutical players include Takeda, Astellas, and Novartis.
- Several patents on similar compounds are filed in the same period.
- Some prior art patents disclose structurally similar compounds with different substituents, potentially challenging JP2015205903’s claims.
Key considerations for patent strength:
- Novelty: The compound features unique substituents or stereochemistry not disclosed in prior art.
- Inventive step: The synthesis route offers improvements over existing methods or addresses specific pharmacokinetic issues.
- Coverage: Claims include a broad core structure, offering extensive protection, but narrowing focus may risk prior art challenges.
Summary of the patent landscape and strategic implications:
- The patent occupies a niche in kinase inhibitor chemistry.
- Similar patents exist but do not disclose the exact claimed structure.
- The scope appears sufficiently broad to cover key derivatives, but ongoing patent filings by competitors could restrict future claims.
- Patent expiry is likely in 2034-2036, assuming maintenance fees are paid in all jurisdictions.
Key Takeaways
- JP2015205903 claims a specific chemical structure with pharmaceutical applications, mainly for kinase-related diseases.
- The patent’s scope covers both the compound and methods of synthesis, with claims extending to pharmaceutical formulations.
- The patent landscape includes numerous similar kinase inhibitor patents, indicating a competitive environment.
- Prior art may challenge the novelty or inventive step of specific claims, especially where structural similarities exist.
- Maintaining patent strength requires clear differentiation from existing compounds and comprehensive claim coverage.
FAQs
Q1: How does JP2015205903 differ from similar patents on kinase inhibitors?
A1: It claims a unique chemical structure with specific substituents and stereochemistry not disclosed in prior art, providing potentially broad protection.
Q2: What are the limitations of the patent claims?
A2: The claims are limited to particular substituents and stereochemistry; structural modifications outside these parameters may fall outside the patent scope.
Q3: Can derivatives of the compound be patented separately?
A3: Yes, if they fall outside the scope of existing claims or involve novel structural modifications, they can warrant new patents.
Q4: What is the typical patent life for this patent?
A4: Assuming maintenance fees are paid, expiry is around 2034-2036, considering Japan’s 20-year patent term from filing.
Q5: How does prior art affect enforceability?
A5: Overlapping existing patents may lead to validity challenges. Clear claims and evidence of inventiveness are crucial for enforceability.
References
- Takeda Pharmaceutical Company Limited. (2018). Patent JP2015205903. Japan Patent Office.
- World Intellectual Property Organization. (2013). WO2014208436A1.
- Japan Patent Office. (2014). JP2014103449.
- United States Patent and Trademark Office. (2012). US8541283B.
